These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 10586190)
21. Epidemiology, symptomatology and treatment of patients with myasthenia gravis in an Australian hospital. Li V; Jasinarachchi M; Butler E Intern Med J; 2019 Dec; 49(12):1537-1540. PubMed ID: 31808263 [TBL] [Abstract][Full Text] [Related]
22. Intravenous immunoglobulin for preparing myasthenia gravis patients for thymectomy and other surgical procedures preventing myasthenic crisis. Gamez J Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):134-5. PubMed ID: 25546793 [No Abstract] [Full Text] [Related]
24. Therapeutic plasma exchange in a patient of myasthenic crisis, refractory to intravenous immunoglobulin and immunosuppressive therapy. Prakash S; Hans R; Sharma RR; Lal V; Marwaha N Neurol India; 2017; 65(6):1409-1412. PubMed ID: 29133726 [No Abstract] [Full Text] [Related]
25. Myasthenia Gravis. Gilhus NE N Engl J Med; 2016 Dec; 375(26):2570-2581. PubMed ID: 28029925 [No Abstract] [Full Text] [Related]
26. IVIg in the chronic management of myasthenia gravis: is it enough for your money? Dalakas MC J Neurol Sci; 2014 Mar; 338(1-2):1-2. PubMed ID: 24411405 [No Abstract] [Full Text] [Related]
27. A treatment algorithm for autoimmune myasthenia gravis in childhood. Andrews PI Ann N Y Acad Sci; 1998 May; 841():789-802. PubMed ID: 9668332 [No Abstract] [Full Text] [Related]
28. Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. Heatwole C; Johnson N; Holloway R; Noyes K J Clin Neuromuscul Dis; 2011 Dec; 13(2):85-94. PubMed ID: 22361692 [TBL] [Abstract][Full Text] [Related]
29. Neonatal myasthenia. Dunn JM Am J Obstet Gynecol; 1976 May; 125(2):265-6. PubMed ID: 1266906 [No Abstract] [Full Text] [Related]
31. IVIG and PLEX in the treatment of myasthenia gravis. Bril V; Barnett-Tapia C; Barth D; Katzberg HD Ann N Y Acad Sci; 2012 Dec; 1275():1-6. PubMed ID: 23278570 [TBL] [Abstract][Full Text] [Related]
32. Potential predictors of response to immunomodulation in patients with myasthenia gravis. Li HF; Liu T; Hong Y; Zhang HL Muscle Nerve; 2012 Dec; 46(6):982-3; author reply 983. PubMed ID: 23225397 [No Abstract] [Full Text] [Related]
33. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Zinman L; Ng E; Bril V Neurology; 2007 Mar; 68(11):837-41. PubMed ID: 17353471 [TBL] [Abstract][Full Text] [Related]
34. Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis. Furlan JC; Barth D; Barnett C; Bril V Muscle Nerve; 2016 Jun; 53(6):872-6. PubMed ID: 26521889 [TBL] [Abstract][Full Text] [Related]
35. A comparison between IVIG and plasma exchange as preparations before thymectomy in myasthenia gravis patients. Alipour-Faz A; Shojaei M; Peyvandi H; Ramzi D; Oroei M; Ghadiri F; Peyvandi M Acta Neurol Belg; 2017 Mar; 117(1):245-249. PubMed ID: 27530310 [TBL] [Abstract][Full Text] [Related]
40. Expanding the evidence base for therapeutics in myasthenia gravis. Miller RG; Barohn RJ; Dubinsky R Ann Neurol; 2010 Dec; 68(6):776-7. PubMed ID: 21194147 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]